3B Blackbio DX Ltd
₹ 1,355
-2.37%
22 Apr
- close price
About
Incorporated in 2011, 3B BlackBio Dx Ltd manufactures and exports PCR based Molecular Diagnostic kits, PCR Enzymes & PCR Reagents, and agrochemical-based products[1]
Key Points
- Market Cap ₹ 1,166 Cr.
- Current Price ₹ 1,355
- High / Low ₹ 2,020 / 1,110
- Stock P/E 22.8
- Book Value ₹ 346
- Dividend Yield 0.30 %
- ROCE 25.5 %
- ROE 19.0 %
- Face Value ₹ 10.0
Pros
- Company has reduced debt.
- Company is almost debt free.
- Company has delivered good profit growth of 139% CAGR over last 5 years
- Debtor days have improved from 179 to 142 days.
Cons
- Earnings include an other income of Rs.17.8 Cr.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Healthcare Services Healthcare Service Provider
Part of BSE Healthcare
Loading peers table ...
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 21 | 18 | 16 | 13 | 16 | 12 | 14 | 14 | 16 | 59 | 71 | 91 | 96 | |
| 20 | 17 | 15 | 12 | 14 | 12 | 14 | 16 | 17 | 30 | 36 | 41 | 44 | |
| Operating Profit | 1 | 1 | 1 | 1 | 1 | 0 | -0 | -1 | -1 | 30 | 35 | 50 | 51 |
| OPM % | 6% | 7% | 7% | 8% | 7% | 4% | -2% | -8% | -8% | 50% | 50% | 55% | 54% |
| 0 | 0 | 0 | 0 | 0 | 1 | 1 | 4 | 10 | 7 | 12 | 15 | 18 | |
| Interest | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 |
| Profit before tax | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 2 | 8 | 36 | 46 | 64 | 68 |
| Tax % | 14% | 21% | 23% | 14% | 9% | 2% | 0% | 18% | 5% | 26% | 26% | 26% | |
| 0 | 0 | 0 | 0 | 1 | 0 | 1 | 2 | 8 | 26 | 34 | 48 | 51 | |
| EPS in Rs | 0.59 | 0.34 | 0.30 | 0.36 | 0.81 | 0.67 | 0.81 | 2.29 | 10.67 | 35.19 | 39.86 | 55.41 | 59.55 |
| Dividend Payout % | 0% | 0% | 0% | 83% | 61% | 74% | 86% | 392% | 98% | 8% | 8% | 7% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 18% |
| 5 Years: | 46% |
| 3 Years: | 80% |
| TTM: | 7% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 71% |
| 5 Years: | 139% |
| 3 Years: | 81% |
| TTM: | 8% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 64% |
| 5 Years: | 29% |
| 3 Years: | 46% |
| 1 Year: | -25% |
| Return on Equity | |
|---|---|
| 10 Years: | 17% |
| 5 Years: | 19% |
| 3 Years: | 19% |
| Last Year: | 19% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 6 | 6 | 6 | 6 | 6 | 6 | 7 | 7 | 7 | 9 | 9 | 9 | 9 |
| Reserves | 4 | 4 | 5 | 5 | 9 | 9 | 13 | 15 | 16 | 188 | 219 | 264 | 289 |
| 6 | 7 | 7 | 8 | 6 | 6 | 4 | 2 | 3 | 2 | 1 | 0 | 0 | |
| 7 | 7 | 6 | 5 | 5 | 5 | 4 | 4 | 5 | 16 | 21 | 24 | 16 | |
| Total Liabilities | 24 | 25 | 24 | 24 | 26 | 27 | 28 | 29 | 32 | 214 | 250 | 297 | 314 |
| 3 | 3 | 3 | 3 | 2 | 2 | 2 | 2 | 3 | 7 | 7 | 6 | 7 | |
| CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 1 | 1 | 1 | 4 | 4 | 4 | 102 | 128 | 167 | 186 |
| 21 | 22 | 21 | 21 | 22 | 23 | 22 | 23 | 25 | 105 | 116 | 124 | 121 | |
| Total Assets | 24 | 25 | 24 | 24 | 26 | 27 | 28 | 29 | 32 | 214 | 250 | 297 | 314 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0 | 0 | 1 | 0 | -1 | 0 | 1 | 3 | 8 | 21 | 28 | 44 | |
| -0 | -0 | -0 | 0 | -0 | -0 | -2 | -0 | -2 | -8 | -20 | -34 | |
| 0 | -0 | -1 | -0 | 1 | -0 | 1 | -2 | -6 | -3 | -4 | -3 | |
| Net Cash Flow | 0 | 0 | 0 | 0 | 0 | -0 | 0 | 1 | 0 | 10 | 5 | 8 |
| Free Cash Flow | 0 | 0 | 1 | 0 | -1 | 0 | 1 | 3 | 6 | 20 | 28 | 44 |
| CFO/OP | 24% | 21% | 87% | 26% | -63% | 107% | -458% | -264% | -663% | 102% | 112% | 119% |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 217 | 271 | 303 | 371 | 332 | 426 | 382 | 358 | 337 | 206 | 188 | 142 |
| Inventory Days | 106 | 128 | 121 | 190 | 108 | 176 | 116 | 88 | 81 | 154 | 144 | 122 |
| Days Payable | 175 | 204 | 190 | 237 | 115 | 156 | 108 | 95 | 108 | 63 | 65 | 24 |
| Cash Conversion Cycle | 148 | 196 | 234 | 323 | 326 | 447 | 390 | 351 | 311 | 297 | 267 | 240 |
| Working Capital Days | 150 | 183 | 218 | 279 | 328 | 427 | 438 | 422 | 391 | 248 | 225 | 174 |
| ROCE % | 7% | 6% | 5% | 6% | 6% | 4% | 4% | 9% | 34% | 32% | 22% | 26% |
Insights
In beta| Mar 2019 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|
| Domestic Lab/Hospital Reach Number |
|
|||
| Global Presence (Countries) Number |
||||
| MDx Research & Development (R&D) Spend as % of Turnover % |
||||
| Number of Agrochemical Dealers Number |
||||
| Number of Molecular Diagnostic Assays Developed Number |
||||
| Capacity Utilization (Diagnostic Kits) % |
||||
| Number of Agrochemical Products (Biologicals) Number |
||||
| Number of Agrochemical Products (Chemicals) Number |
||||
| Domestic Customer Access (India Cities) Number |
||||
| Long-term Reagent-Rental Contracts Number |
||||
| Molecular Diagnostics (MDx) Market Share in India % |
||||
| R&D Expenditure (Percentage of Turnover) % |
||||
Requires Premium
Requires Premium
Extracted by Screener AI
Documents
Announcements
-
Securities Of The Companies Permitted To Trade And Admitted To Dealings On The National Stock Exchange
1d - 3B BlackBio Dx shares admitted for NSE trading from April 20, 2026.
-
Format of the Annual Disclosure to be made by an entity identified as a LC - Annexure B2
15 Apr - Company confirmed it is not a Large Corporate under SEBI disclosure norms.
-
Format of the Annual Disclosure to be made by an entity identified as a LC - Annexure B2
15 Apr - Company confirms it is not a Large Corporate under SEBI circular.
-
Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A
14 Apr - 3B BlackBio Dx confirms it is not a Large Corporate under SEBI circular.
- Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 6 Apr
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
Concalls
-
Feb 2026Transcript PPT REC
-
Nov 2025TranscriptAI SummaryPPT
-
Aug 2025Transcript PPT REC
-
May 2025TranscriptAI SummaryPPT
-
Feb 2025TranscriptAI SummaryPPT
-
Nov 2024TranscriptAI SummaryPPT
-
Aug 2024TranscriptAI SummaryPPT
-
May 2024TranscriptAI SummaryPPT
-
Feb 2024TranscriptAI SummaryPPT
-
Nov 2023TranscriptAI SummaryPPT
-
Aug 2023TranscriptAI SummaryPPT
-
May 2023TranscriptAI SummaryPPT
-
Feb 2023TranscriptAI SummaryPPT
-
Nov 2022TranscriptAI SummaryPPT
-
Sep 2022TranscriptAI SummaryPPT
-
Aug 2022TranscriptAI SummaryPPT
-
May 2022TranscriptAI SummaryPPT
-
Feb 2022TranscriptAI SummaryPPT
-
Nov 2021TranscriptAI SummaryPPT
-
Sep 2021TranscriptAI SummaryPPT
-
Jul 2021TranscriptAI SummaryPPT
-
Jun 2021TranscriptAI SummaryPPT
-
Feb 2021TranscriptAI SummaryPPT
-
Feb 2021TranscriptAI SummaryPPT
-
Nov 2020TranscriptAI SummaryPPT
-
Sep 2020TranscriptAI SummaryPPT
-
Jul 2020TranscriptAI SummaryPPT
-
Jun 2020TranscriptAI SummaryPPT
-
Feb 2020TranscriptAI SummaryPPT
-
Nov 2019TranscriptAI SummaryPPT
-
Jul 2019TranscriptAI SummaryPPT
-
May 2019TranscriptAI SummaryPPT
-
Jan 2019TranscriptAI SummaryPPT
-
Nov 2018TranscriptAI SummaryPPT
-
Aug 2018TranscriptAI SummaryPPT
-
May 2018TranscriptAI SummaryPPT
-
Feb 2018TranscriptAI SummaryPPT
-
Nov 2017TranscriptAI SummaryPPT
-
Jul 2017TranscriptAI SummaryPPT
-
Feb 2017TranscriptAI SummaryPPT
Business Segments[1][2]
A) Diagnostics Business (81% of FY23 revenue)
3BDL is part of an Indo-Spanish JV and was formed by amalgamation with its parent company Kilpest India Limited. Company is an ISO 13485:2016 certified, GMP-compliant biotech R&D organization and is engaged in the design, development, manufacturing, and commercialization of Rapid tests, PCR-based Molecular Diagnostic kits, PCR Enzymes & PCR Reagents, NGS-based Molecular Diagnostic Kit